{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:18:52Z","timestamp":1789651132483,"version":"4.0.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Myocardial infarction survivors are at a high risk of a recurrent event despite receiving guideline preventive therapy. There is accumulated evidence that persistent atherosclerotic plaque inflammation contributes to this risk. Oxidized low-density lipoprotein (LDL) is widely recognized as a key factor in plaque inflammation and instability; however, no therapies that directly target oxidized LDL are to date available for clinical use. We will here review recent observations indicating that treatment with the anti-oxidized LDL antibody orticumab specifically inhibits plaque inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The effect of orticumab on coronary inflammation in a randomized, double-blind, placebo-controlled pilot phase 2a trial in subjects with moderate to severe psoriasis is a new and recent finding. Coronary inflammation was assessed by calculation of the fat attenuation index (FAI)-Score in the pericoronary adipose tissue in coronary computed tomography angiograms. After 15\u200aweeks of treatment the mean FAI-Score of the three main coronary arteries was significantly reduced in the orticumab group while no change occurred in the placebo group. The effect of orticumab was most pronounced in those with most inflammation at baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Treatment with orticumab represents a new and plaque-specific way to reduce arterial inflammation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000990","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:00:34Z","timestamp":1745845234000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy"],"prefix":"10.1097","volume":"36","author":[{"given":"Christopher J.","family":"Farina","sequence":"first","affiliation":[{"name":"Abcentra, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Lu","sequence":"additional","affiliation":[{"name":"Abcentra, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Abcentra, Los Angeles, California, USA"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R1-20250703","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20250703","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists Collaboration","year":"2015","journal-title":"Lancet"},{"key":"R3-20250703","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R4-20250703","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.103.7.926","article-title":"Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization","volume":"103","author":"Crisby","year":"2001","journal-title":"Circulation"},{"key":"R5-20250703","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R6-20250703","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1161\/01.ATV.0000033829.14012.18","article-title":"Oxidized LDL in carotid plaques and plasma associates with plaque instability","volume":"22","author":"Nishi","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R7-20250703","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12933-020-01189-z","article-title":"Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events","volume":"19","author":"Singh","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"R8-20250703","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"R9-20250703","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20250703","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/ATVBAHA.124.319851","article-title":"Colchicine's role in cardiovascular disease management","volume":"44","author":"Buckley","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-20250703","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis: the road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell"},{"key":"R12-20250703","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"R13-20250703","doi-asserted-by":"crossref","first-page":"11386","DOI":"10.3390\/ijms252111386","article-title":"Oxidized low-density lipoprotein and its role in immunometabolism","volume":"25","author":"Mosalmanzadeh","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R14-20250703","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.atherosclerosis.2008.11.020","article-title":"Identification of the target for therapeutic recombinant antiapoB-100 peptide antibodies in human atherosclerotic lesions","volume":"205","author":"Goncalves","year":"2009","journal-title":"Atherosclerosis"},{"key":"R15-20250703","doi-asserted-by":"crossref","first-page":"418313","DOI":"10.1155\/2011\/418313","article-title":"The dynamics of oxidized LDL during atherogenesis","volume":"2011","author":"Itabe","year":"2011","journal-title":"J Lipids"},{"key":"R16-20250703","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"R17-20250703","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM200001203420302","article-title":"Vitamin E supplementation and cardiovascular events in high-risk patients","volume":"342","author":"Heart Outcomes Prevention Evaluation Study I.","year":"2000","journal-title":"N Engl J Med"},{"key":"R18-20250703","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/ATVBAHA.112.249854","article-title":"Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation","volume":"32","author":"Goncalves","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-20250703","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune effector mechanisms implicated in atherosclerosis: from mice to humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity"},{"key":"R20-20250703","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","article-title":"Trained immunity \u2013 basic concepts and contributions to immunopathology","volume":"19","author":"Ochando","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"R21-20250703","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature"},{"key":"R22-20250703","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/eurheartj\/ehad787","article-title":"Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis","volume":"45","author":"Dong","year":"2024","journal-title":"Eur Heart J"},{"key":"R23-20250703","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cvr\/cvac161","article-title":"Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis","volume":"119","author":"Zernecke","year":"2023","journal-title":"Cardiovasc Res"},{"key":"R24-20250703","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s44161-023-00354-3","article-title":"Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis","volume":"2","author":"Patterson","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"R25-20250703","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s44161-024-00429-9","article-title":"TREM2 protects from atherosclerosis by limiting necrotic core formation","volume":"3","author":"Piollet","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"R26-20250703","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s44161-023-00295-x","article-title":"Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications","volume":"2","author":"Dib","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"R27-20250703","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"R28-20250703","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(24)00596-8","article-title":"Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study","volume":"403","author":"Chan","year":"2024","journal-title":"Lancet"},{"key":"R29-20250703","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/joim.12353","article-title":"Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges","volume":"278","author":"Nilsson","year":"2015","journal-title":"J Intern Med"},{"key":"R30-20250703","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/ATVBAHA.124.319843","article-title":"Role of antibodies and their specificities in atherosclerotic cardiovascular disease","volume":"44","author":"Deroissart","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R31-20250703","first-page":"2544","article-title":"Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies","volume":"117","author":"Porsch","year":"2021","journal-title":"Cardiovasc Res"},{"key":"R32-20250703","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.hlc.2023.09.006","article-title":"Persistence of detectable anti-pneumococcal antibodies 4 years after pneumococcal polysaccharide vaccination in a randomised controlled trial: the Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE)","volume":"11","author":"Attia","year":"2023","journal-title":"Heart Lung Circ"},{"key":"R33-20250703","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurheartj\/ehn336","article-title":"High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction","volume":"29","author":"Sjogren","year":"2008","journal-title":"Eur Heart J"},{"key":"R34-20250703","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/ATVBAHA.115.306938","article-title":"Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events","volume":"36","author":"Bjorkbacka","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-20250703","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.116.012677","article-title":"Apolipoprotein B-100 antibody interaction with atherosclerotic plaque inflammation and repair processes","volume":"47","author":"Asciutto","year":"2016","journal-title":"Stroke"},{"key":"R36-20250703","first-page":"172","article-title":"Multiradionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoprotein","volume":"4","author":"Orbom","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R37-20250703","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"key":"R38-20250703","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2007.07.081","article-title":"Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-\/-)\/low-density lipoprotein receptor(-\/-) mice","volume":"50","author":"Schiopu","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R39-20250703","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.atherosclerosis.2006.03.032","article-title":"Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100","volume":"190","author":"Strom","year":"2006","journal-title":"Atherosclerosis"},{"key":"R40-20250703","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molmet.2013.06.001","article-title":"Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques","volume":"2","author":"Li","year":"2013","journal-title":"Mol Metab"},{"key":"R41-20250703","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.4049\/jimmunol.0902654","article-title":"FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"184","author":"Zhao","year":"2010","journal-title":"J Immunol"},{"key":"R42-20250703","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.atherosclerosis.2010.10.018","article-title":"The inhibitory FcgammaRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-\/-) mice","volume":"214","author":"Mendez-Fernandez","year":"2011","journal-title":"Atherosclerosis"},{"key":"R43-20250703","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/cvr\/cvae057","article-title":"Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial","volume":"120","author":"Farina","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:00:34Z","timestamp":1751533234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000990","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}